Gwo Xi Stem Cell Applied Technology Co. , Ltd (TPEX:6704)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
19.40
-0.30 (-1.52%)
Jul 14, 2026, 1:41 PM CST
Market Cap1.89B -27.3%
Revenue (ttm)187.02M +10.0%
Net Income-80.52M
EPS-0.84
Shares Out 95.95M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,001
Open20.25
Previous Close19.70
Day's Range19.40 - 20.50
52-Week Range18.85 - 33.65
Beta0.07
Analystsn/a
Price Targetn/a
Earnings DateAug 13, 2026

About TPEX:6704

Gwo Xi Stem Cell Applied Technology Co. , Ltd develops stem cell technology for patients with unmet medical needs. Its products under development include GXHPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of liver cirrhosis; and GXNPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of chronic stroke. The company is also developing GXCPC1, an allogeneic adipose-derived stem cells therapy in phase I/II clinical trials for use in the tr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 55
Stock Exchange Taipei Exchange
Ticker Symbol 6704
Full Company Profile

Financial Performance

In 2025, TPEX:6704's revenue was 187.02 million, an increase of 10.00% compared to the previous year's 170.03 million. Losses were -80.52 million, -3.36% less than in 2024.

Financial Statements